|
124 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
11 Trials |
|
2428 News |
|
| «12...38394041424344454647484950» |
- ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Enrollment change: HEPCPR: Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients (clinicaltrials.gov) - May 15, 2012
P2, N=40, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=180 --> 40
- Adherence: A Commitment Device for Medication Adherence Among HIV Patients (clinicaltrials.gov) - May 15, 2012
P=N/A, N=40, Active, not recruiting, Sponsor: National Bureau of Economic Research, Inc.
N=180 --> 40 Enrolling by invitation --> Active, not recruiting
- Pifeltro (doravirine) / Merck (MSD)
Enrollment change: A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005) (clinicaltrials.gov) - May 14, 2012
P1, N=18, Completed, Sponsor: Merck
Enrolling by invitation --> Active, not recruiting N=26 --> 18
- stavudine / Generic mfg., zidovudine / Generic mfg.
Enrollment change, Adverse events: Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine (clinicaltrials.gov) - May 14, 2012
P2, N=3, Completed, Sponsor: National Center for Complementary and Alternative Medicine (NCCAM)
N=26 --> 18 N=20 --> 3
- Pifeltro (doravirine) / Merck (MSD)
Trial completion: A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005) (clinicaltrials.gov) - May 14, 2012
P1, N=18, Completed, Sponsor: Merck
N=20 --> 3 Recruiting --> Completed
- stavudine / Generic mfg., zidovudine / Generic mfg.
Trial completion, Adverse events: Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine (clinicaltrials.gov) - May 14, 2012
P2, N=3, Completed, Sponsor: National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting --> Completed Recruiting --> Completed
- ||||||| Edurant (rilpivirine) / J&J
Trial completion, Combination therapy: TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (clinicaltrials.gov) - May 13, 2012
P3, N=680, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission (clinicaltrials.gov) - May 13, 2012
P3, N=6203, Completed, Sponsor: Population Council
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Selzentry (maraviroc) / ViiV Healthcare
New P1 trial: A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir (clinicaltrials.gov) - May 10, 2012
P1, N=42, Completed, Sponsor: GlaxoSmithKline
- aripiprazole / Generic mfg., methamphetamine / Generic mfg.
Trial completion: Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals (clinicaltrials.gov) - May 8, 2012
P2, N=90, Completed, Sponsor: San Francisco Department of Public Health
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| Trial completion: Glizigen-Viudid-External Anogenital Warts in Children and Adolescents (clinicaltrials.gov) - May 5, 2012
P3, N=76, Completed, Sponsor: Catalysis SL
Recruiting --> Completed Recruiting --> Completed
- | Vocabria (cabotegravir oral) / ViiV Healthcare
New P1 trial: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects (clinicaltrials.gov) - May 3, 2012
P1, N=43, Completed, Sponsor: ViiV Healthcare
- Enrollment open: Treatment Advocacy Intervention for HIV-Positive African Americans (clinicaltrials.gov) - May 2, 2012
P2, N=200, Recruiting, Sponsor: Children's Hospital Boston
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Enrollment change: Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings (clinicaltrials.gov) - May 1, 2012
P2, N=270, Completed, Sponsor: Novartis Vaccines
Not yet recruiting --> Recruiting N=180 --> 270
- Enrollment change: HIV Resistance and Treatment Strategies (clinicaltrials.gov) - May 1, 2012
P=N/A, N=89, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=180 --> 270 N=300 --> 89
- Trial completion: HIV Resistance and Treatment Strategies (clinicaltrials.gov) - May 1, 2012
P=N/A, N=89, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=300 --> 89 Recruiting --> Completed
- Enrollment open: Early Antiviral Therapy for Critically Ill HIV Infected Patients (clinicaltrials.gov) - Apr 30, 2012
P4, N=344, Recruiting, Sponsor: Hospital Nossa Senhora da Conceicao
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Intelence (etravirine) / J&J
Trial completion, Combination therapy: TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients (clinicaltrials.gov) - Apr 30, 2012
P2, N=50, Completed, Sponsor: Janssen R&D Ireland
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment change: Specialized Cognitive-Behavioral Counseling Intervention to Reduce HIV Transmission Risk Behavior in HIV-Infected Men (clinicaltrials.gov) - Apr 29, 2012
P=N/A, N=488, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed N=376 --> 488
- Trial completion: Specialized Cognitive-Behavioral Counseling Intervention to Reduce HIV Transmission Risk Behavior in HIV-Infected Men (clinicaltrials.gov) - Apr 29, 2012
P=N/A, N=488, Completed, Sponsor: University of California, San Francisco
N=376 --> 488 Recruiting --> Completed
- cyclophosphamide / Generic mfg.
Trial initiation date, Combination therapy: Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients (clinicaltrials.gov) - Apr 26, 2012
P1, N=21, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Completed Initiation date: Dec 2011 --> Apr 2012
- cyclophosphamide / Generic mfg.
Enrollment open, Combination therapy: Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients (clinicaltrials.gov) - Apr 26, 2012
P1, N=21, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Initiation date: Dec 2011 --> Apr 2012 Not yet recruiting --> Recruiting
- ||| Trial completion: Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP (clinicaltrials.gov) - Apr 26, 2012
P=N/A, N=2808, Completed, Sponsor: Chembio Diagnostic Systems, Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed
- BMS707035 / BMS
Trial withdrawal: A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects (clinicaltrials.gov) - Apr 25, 2012
P2, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed Terminated --> Withdrawn
- efavirenz / Generic mfg.
Trial termination: Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET) (clinicaltrials.gov) - Apr 25, 2012
P2, N=23, Terminated, Sponsor: ViiV Healthcare
Terminated --> Withdrawn Not yet recruiting --> Terminated
- efavirenz / Generic mfg.
Enrollment change: Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET) (clinicaltrials.gov) - Apr 25, 2012
P2, N=23, Terminated, Sponsor: ViiV Healthcare
Not yet recruiting --> Terminated N=150 --> 23
- BMS707035 / BMS
Enrollment change: A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects (clinicaltrials.gov) - Apr 25, 2012
P2, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
N=150 --> 23 N=50 --> 0
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: Dolutegravir Renal Impairment Study (clinicaltrials.gov) - Apr 25, 2012
P1, N=16, Completed, Sponsor: ViiV Healthcare
N=50 --> 0 Recruiting --> Completed
- ||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: Safety and Efficacy of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Apr 24, 2012
P2, N=150, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment closed: A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects (clinicaltrials.gov) - Apr 24, 2012
P1/2, N=21, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- fenofibrate / Generic mfg.
Trial completion: HeartPositive: Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia (clinicaltrials.gov) - Apr 24, 2012
P=N/A, N=221, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial termination: ISS OBS T-002: Observational Study on Anti-Tat Immune Response in HIV-1-infected HAART-treated Adult Subjects (clinicaltrials.gov) - Apr 23, 2012
P=N/A, N=0, Terminated, Sponsor: Istituto Superiore di Sanita
Active, not recruiting --> Completed Recruiting --> Terminated
- acyclovir / Generic mfg.
Enrollment change: PK/GUD: GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women (clinicaltrials.gov) - Apr 19, 2012
P=N/A, N=88, Completed, Sponsor: University of Washington
Recruiting --> Terminated N=156 --> 88
- | Veregen (sinecatechins) / Sinphar Pharma, Medigene
Trial completion: Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers (clinicaltrials.gov) - Apr 17, 2012
P1, N=30, Completed, Sponsor: MediGene
N=156 --> 88 Recruiting --> Completed
- | Isentress (raltegravir) / Merck (MSD)
Trial completion: RALPIR: Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria (clinicaltrials.gov) - Apr 17, 2012
P4, N=20, Completed, Sponsor: Metropolis Medical
Recruiting --> Completed Recruiting --> Completed
- Trial initiation date: Intervention to Retain HIV-positive Patients in Medical Care (clinicaltrials.gov) - Apr 15, 2012
P=N/A, N=1838, Completed, Sponsor: Centers for Disease Control and Prevention
Recruiting --> Completed Initiation date: Mar 2010 --> Jul 2010
- Enrollment change: Community-based Evaluation of a Pilot PMTCT Project in Kafue District (clinicaltrials.gov) - Apr 15, 2012
P=N/A, N=4129, Completed, Sponsor: University of North Carolina, Chapel Hill
Initiation date: Mar 2010 --> Jul 2010 N=1548 --> 4129
- Trial completion: Community-based Evaluation of a Pilot PMTCT Project in Kafue District (clinicaltrials.gov) - Apr 15, 2012
P=N/A, N=4129, Completed, Sponsor: University of North Carolina, Chapel Hill
N=1548 --> 4129 Active, not recruiting --> Completed
- Trial completion: Project TRAC: Affect Management Intervention for Early Adolescents Wtih Mental Health Problems (clinicaltrials.gov) - Apr 11, 2012
P1, N=138, Completed, Sponsor: Rhode Island Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Response to Standard HIV Treatment in Bamako, Mali (clinicaltrials.gov) - Apr 11, 2012
P=N/A, N=0, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial termination: Toxicity Substudy of Evaluation of Subcutaneous Proleukin in a Randomised International Trial (ESPRIT): TOXIL-2 Substudy (clinicaltrials.gov) - Apr 10, 2012
P3, N=28, Terminated, Sponsor: Kirby Institute
Active, not recruiting --> Completed Active, not recruiting --> Terminated; 28 of 168 patients only were enrolled, numbers too low to be conclusive
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Enrollment change: Toxicity Substudy of Evaluation of Subcutaneous Proleukin in a Randomised International Trial (ESPRIT): TOXIL-2 Substudy (clinicaltrials.gov) - Apr 10, 2012
P3, N=28, Terminated, Sponsor: Kirby Institute
Active, not recruiting --> Terminated; 28 of 168 patients only were enrolled, numbers too low to be conclusive N=168 --> 28
- | Isentress (raltegravir) / Merck (MSD)
New P4 trial: Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP) (clinicaltrials.gov) - Apr 10, 2012
P4, N=240, Recruiting, Sponsor: Hospital Clinic of Barcelona
- Selzentry (maraviroc) / ViiV Healthcare
Trial completion: SSAT033: PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing Regimen (clinicaltrials.gov) - Apr 10, 2012
P4, N=12, Completed, Sponsor: St Stephens Aids Trust
N=168 --> 28 Recruiting --> Completed
- Trial completion: HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) (clinicaltrials.gov) - Apr 10, 2012
P4, N=80, Completed, Sponsor: Kirby Institute
Recruiting --> Completed Active, not recruiting --> Completed
- lopinavir/ritonavir / Generic mfg., lamivudine/zidovudine / Generic mfg.
Trial completion: Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir (clinicaltrials.gov) - Apr 10, 2012
P4, N=50, Completed, Sponsor: Kirby Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Trial completion: SPARTA: Raltegravir and Atazanavir Dosing Strategy Study (clinicaltrials.gov) - Apr 9, 2012
P3, N=26, Completed, Sponsor: Kirby Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- nevirapine / Generic mfg.
Trial completion: Mashi: Prevention of Milk-Borne Transmission of HIV-1C in Botswana (clinicaltrials.gov) - Apr 8, 2012
P=N/A, N=1200, Completed, Sponsor: Harvard School of Public Health
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Integration of HIV Care and Treatment Into Antenatal Care in Migori District, Kenya (clinicaltrials.gov) - Apr 5, 2012
P=N/A, N=1172, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Edurant (rilpivirine) / J&J
Trial completion: A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines (clinicaltrials.gov) - Apr 5, 2012
P2b, N=372, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed